Co-Authors
This is a "connection" page, showing publications co-authored by Hua Chen and Susan Abughosh.
Connection Strength
4.123
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.240
-
Group-based trajectory modeling to identify adherence patterns for direct oral anticoagulants in Medicare beneficiaries with atrial fibrillation: a real-world study on medication adherence. Int J Clin Pharm. 2024 Dec; 46(6):1525-1535.
Score: 0.240
-
Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024 10; 34(8):359-365.
Score: 0.240
-
Trajectories and Predictors for the Development of Clinically Significant Weight Gain in Children and Adolescents Prescribed Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2024 05; 34(4):201-209.
Score: 0.232
-
Group-Based Trajectory Modeling to Identify Patterns of Antipsychotic-Associated Weight Gain Among Children and Adolescents. J Clin Psychopharmacol. 2024 Mar-Apr 01; 44(2):124-132.
Score: 0.230
-
Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
Score: 0.225
-
Association Between Abnormal Metabolic Parameters and Receiving Subsequent Interventions in Children and Adolescents Initiating Second-Generation Antipsychotics. J Child Adolesc Psychopharmacol. 2023 09; 33(7):269-278.
Score: 0.224
-
Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
Score: 0.222
-
Association of Puberty Stage and Weight Status with Cardiometabolic Risk in Children and Adolescents Living on the Texas-Mexico Border. Metab Syndr Relat Disord. 2022 10; 20(8):440-450.
Score: 0.207
-
Evaluating adherence to concomitant diabetes, hypertension, and hyperlipidemia treatments and intermediate outcomes among elderly patients using marginal structural modeling. Pharmacotherapy. 2022 07; 42(7):518-528.
Score: 0.206
-
Association of the Healthcare Effectiveness Data and Information Set (HEDIS) Follow-Up Care Measures and Medication Adherence Among Medicaid Insured Children with ADHD. J Atten Disord. 2022 Feb; 26(3):370-376.
Score: 0.187
-
Risk of Cardiovascular Outcomes and Antihypertensive Triple Combination Therapy Among Elderly Patients with Hypertension Enrolled in a Medicare Advantage Plan (MAP). Am J Cardiovasc Drugs. 2020 Dec; 20(6):591-602.
Score: 0.185
-
Cost-effectiveness analysis of antihypertensive triple combination therapy among patients enrolled in a Medicare advantage plan. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):829-836.
Score: 0.181
-
A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy. Medicine (Baltimore). 2020 Apr; 99(16):e19603.
Score: 0.177
-
Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study. Res Pract Thromb Haemost. 2019 Oct; 3(4):674-683.
Score: 0.167
-
Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):678-686.
Score: 0.167
-
Comparison of Suicide Attempts/Behaviors Following Smoking Cessation Treatments Among Schizophrenic Smokers. Arch Psychiatr Nurs. 2017 02; 31(1):62-67.
Score: 0.137
-
Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation. Subst Use Misuse. 2016; 51(5):586-97.
Score: 0.134
-
Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers. Subst Use Misuse. 2015; 50(13):1628-37.
Score: 0.131
-
Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer. Cancers (Basel). 2024 Jun 07; 16(12).
Score: 0.059
-
Development and internal validation of a risk prediction model for HIV disease severity among people living with HIV and mental illness or substance use disorder. Ann Epidemiol. 2023 11; 87:79-92.
Score: 0.056
-
Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023 04 01; 129(7):1051-1063.
Score: 0.054
-
Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb; 198(1):159-166.
Score: 0.054
-
Patterns of Lipid Lowering Therapy Use Among Older Adults in a Managed Care Advantage Plan in the United States. J Pharm Pract. 2024 Feb; 37(1):123-131.
Score: 0.053
-
Assessment of sexually transmitted disease/HIV risk among young African Americans: comparison of self-perceived and epidemiological risks utilizing ecodevelopmental theory. HIV AIDS (Auckl). 2019; 11:31-44.
Score: 0.041
-
HIV-related sexual decisions made by African-American adolescents living in different family structures: study from an ecodevelopmental perspective. HIV AIDS (Auckl). 2018; 10:19-31.
Score: 0.038
-
Modeling ecodevelopmental context of sexually transmitted disease/HIV risk and protective behaviors among African-American adolescents. HIV AIDS (Auckl). 2017; 9:119-135.
Score: 0.036